BioCryst Pharmaceuticals Inc (BCRX) — Cash Flow Quality Index

Latest as of December 2025: 0.76x

BioCryst Pharmaceuticals Inc (BCRX) has a Cash Flow Quality Index of 0.76x as of December 2025. Operating cash flow of $276.04 Million is below net income of $362.26 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore long-term investment intensity of BioCryst Pharmaceuticals Inc to see how much of total assets are deployed in long-term investments.

Cash Flow Quality Index

0.76x
Operating CF / Net Income

Operating Cash Flow

$276.04 Million
USD

Net Income

$362.26 Million
USD

Data as of

Dec 2025
Most recent filing

BioCryst Pharmaceuticals Inc Cash Flow Quality Index (2025–2025)

Historical Cash Flow Quality Index for BioCryst Pharmaceuticals Inc across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check how tangible is BioCryst Pharmaceuticals Inc's equity to evaluate the tangible quality of the company's equity base.

Annual Cash Flow Quality Index for BioCryst Pharmaceuticals Inc (2025–2025)

Year-by-year earnings quality comparison for BioCryst Pharmaceuticals Inc. For live market cap and the full company financial profile, see how much is BioCryst Pharmaceuticals Inc worth.

Year Quality Index Operating CF (USD) Net Income YoY Change
2025 1.25x $329.88 Million $263.86 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.